Looking forward to the following leading up to AGM

Read out on Dep Docetaxel and part of Dep Cabazitaxel

Dep Gemcitabine entering the clinic

Further expansion of indications in clinic for AZD0466

Phase 1/2 combination arm of DEP® irinotecan + 5-FU + Leucovorin (‘FOLFIRI’ entering the clinic

TGA approval for Viraleze in Australia

New partnership agreement with radiotherapeutics

Merck beginning first in human clinical trials with ADC's

FDA NDA update

Monetising undisclosed former blockbuster drug of Astrazeneca with Starpharma's improved version

Sacking of Mundipharma and finding a real partner

Licensing our internal in house Dep drugs



The above is a realistic list of things that I believe can occur over the next 4-5 months

Of course there are many other possibilities..........

Look forward to a very productive quarter